SCHEMBL7215003

SCHEMBL7215003

CC(C)N1CCNC(c2ccccc2)C1C

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 2/20 0.38
KDM4E B2RXH2 1/20 0.37
ALDH1A1 P00352 1/20 0.37
SLC6A2 P23975 1/20 0.36
ADRA1A P35348 1/20 0.36
HTR2B P41595 1/20 0.36
SLC6A3 Q01959 1/20 0.36
HTR1A P08908 1/20 0.35
SLC18A3 Q16572 1/20 0.34
SIGMAR1 Q99720 1/20 0.34
GBA1 P04062 1/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
TACR1 P25103 1/20 0.34
CHRNA7 P36544 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
ACHE P22303 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
TSHR P16473 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL10383318 0.98 HRH3 (0.37) HRH3KDM4EALDH1A1SLC6A2ADRA1A
SCHEMBL10349667 0.74 PRCP (0.41) KDM4EALDH1A1SLC6A2ADRA1AHTR2B
Hydrochloric Acid SCHEMBL10382641 0.73 PRCP (0.40) KDM4EALDH1A1SLC6A2ADRA1AHTR2B
Formamide SCHEMBL28989148 0.71 HTR1A (0.42) KDM4EALDH1A1SLC6A2ADRA1AHTR2B
SCHEMBL3097614 0.69 L3MBTL1 (0.38) L3MBTL1
SCHEMBL4095157 0.69 SLC6A2 (0.41) SLC6A2HTR2BSLC6A3SLC18A3MEN1
SCHEMBL18914200 0.69 SLC6A2 (0.41) SLC6A2HTR2BSLC6A3SLC18A3MEN1
SCHEMBL18913743 0.69 SLC6A2 (0.41) SLC6A2HTR2BSLC6A3SLC18A3MEN1
SCHEMBL8222209 0.68 SLC18A3 (0.52) KDM4EALDH1A1SLC6A2ADRA1AHTR2B
SCHEMBL10349649 0.67 SLC6A2 (0.53) SLC6A2ADRA1AHTR2BSLC6A3SLC18A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0211746-B1 PHENYL-PIPERAZINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THERAPEUTICAL USE LABORATOIRE L. LAFON Société anonyme dite: (FR) 1990-05-23 EP claimed
EP-0211746-A1 Phenyl-piperazine derivatives, process for their preparation and therapeutical use LABORATOIRE L. LAFON Société anonyme dite: (FR) 1987-02-25 EP claimed
US-6603003-B2 Reacting ester with substituted or unsubstituted ethylenediamine to give 3,4-dehydropiperazine-2-one and reacting 3,4-dehydropiperazine-2-one with reducing agent to yield piperazine derivative SUN PHARMACEUTICAL INDUSTRIES LTD (IN) 2003-08-05 US disclosed
US-20020095038-A1 Novel method for the preparation of piperazine and its derivatives SUN PHARMACEUTICAL INDUSTRIES LTD (IN) 2002-07-18 US disclosed
WO-2002038552-A1 A NOVEL METHOD FOR THE PREPARATION OF PIPERAZINE AND ITS DERIVATIVES SUN PHARMACEUTICAL INDUSTRIES LTD. (IN) 2002-05-16 WO disclosed
EP-0211746-B1 PHENYL-PIPERAZINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THERAPEUTICAL USE LABORATOIRE L. LAFON Société anonyme dite: (FR) 1990-05-23 EP disclosed
EP-0211746-B1 PHENYL-PIPERAZINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THERAPEUTICAL USE LABORATOIRE L. LAFON Société anonyme dite: (FR) 1990-05-23 EP disclosed
US-4912110-A Antidepressive substituted phenylpiperazine compounds LABORATOIRE L. LAFTON (FR) 1990-03-27 US disclosed
EP-0211746-A1 Phenyl-piperazine derivatives, process for their preparation and therapeutical use LABORATOIRE L. LAFON Société anonyme dite: (FR) 1987-02-25 EP disclosed
EP-0211746-A1 Phenyl-piperazine derivatives, process for their preparation and therapeutical use LABORATOIRE L. LAFON Société anonyme dite: (FR) 1987-02-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020095038-A1 Novel method for the preparation of piperazine and its derivatives DHPS, DRD4, CYP2E1 HRH3 179/4885KDM4E 525/4885ALDH1A1 116/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.